Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Azacitidine 3venetoclax 1eprenetapopt 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Myeloid Malignancy × Clear all
NCT07263074 2026-03-30

CHORDS

University of Rochester

Phase NA Recruiting
120 enrolled

Myeloid Malignancy

NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

NCT07011186 2025-06-08

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
138 enrolled

Myeloid Malignancy

NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡